Resources
91 Results (showing 21 - 30)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/25/2022 (updated 3/27/2024)
Hepatitis C: State of Medicaid Access is a collaboration between the Center for Health Law and Policy Innovation of Harvard
Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR). The project evaluates hepatitis C (HCV)
treatment restriction policies across state Medicaid programs, including all 50 states, the District of Columbia, and Puerto
Rico (referred to in this report as “states”). The goal of this project is to encourage states and empower advocates to work
toward improved access to curative HCV treatment across all Medicaid programs, in order to ensure that every Medicaid
enrollee who can benefit from this treatment is able to access it.
Posted 12/6/2022 (updated 3/27/2024)
To more effectively address known barriers to treatment for substance use disorder (SUD), policy researchers looked at feedback from 27 community-based programs serving predominantly people of color across the U.S. Beyond poverty and racism, providers describe challenges retaining staff with appropriate language and cultural skills as well as a complex patchwork of social skills.
Posted 4/19/2023 (updated 3/27/2024)
During the initial stages of the Rural Communities Opioid Response Program (RCORP) implementation, lead agencies of RCORP consortia reported difficulty recruiting new members, building key partnerships, and planning and coordinating RCORP-focused activities. Fortunately, with dedication and collaborative work, consortium growth and engagement became successful at the end of the grant period, as reported by 87.5 percent of the grantees. Findings in the report available for download below are based on qualitative interviews conducted with RCORP grantees between 9/1/2020 and 8/31/2022.
Posted 12/13/2022 (updated 3/27/2024)
The data visualization in the National Vital Statistics System, received and processed by the National Center for Health Statistics (NCHS), shows the 12 month provisional number and percent change of drug overdose deaths. The analysis dashboard also shows the provisional number of drug overdose deaths by drug or drug class.
Posted 4/25/2023 (updated 3/27/2024)
This page contains resources to support grantees in collecting, managing and sharing their RCORP data. If you are in need of PIMS data collection guidance, please visit the RCORP Grantee Data Collection Resources (Implementation, MAT Expansion, and NAS) page to access the PIMS Data Collection Resource, checklist, and workbook.
Posted 4/28/2023 (updated 3/27/2024)
With the proliferation of fentanyl and other adulterants in the national illicit drug supply, people who use drugs (PWUD) are at greater risk of overdose. Among more than 107,000 drug overdose deaths that occurred between July 2021–June 2022, 64% involved synthetic opioids like fentanyl. Lowering the high rates of overdose among PWUD is possible, as evidence-based practices exist to prevent and respond to overdose, including fentanyl test strips and advanced drug checking equipment. To inform health departments’ harm reduction programming, the National Council for Mental Wellbeing – with support from the Centers for Disease Control and Prevention – developed Enhancing Harm Reduction Services in Health Departments: Fentanyl Test Strips and Other Drug Checking Equipment, an educational brief grounded by real-world experience.
Posted 10/13/2020 (updated 3/27/2024)
The CDC’s National Vital Statistics System has been updated to now include data related to February 2020 overdose mortality, with trends indicating further worsening of the nation’s opioid epidemic.
Posted 5/19/2023 (updated 3/27/2024)
Public Health Institute's (PHI) Cherished Futures for Black Moms and Babies Program is such an important program and example. Racism and toxic stress are root causes for racial disparities in birth outcomes. PHI’s Cherished Futures for Black Moms and Babies is centering the lived experiences of Black women and birthing parents to address this ongoing maternal mortality crisis, bringing together decision-makers from local hospitals, public health departments, health plans and Black women community leaders to identify and put into action systems-change solutions at clinical, institutional and community levels.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 5/26/2023 (updated 3/27/2024)
More than 450 clinicians and counselors in rural New England were surveyed about stigma as a barrier to treating patients for opioid used disorder (OUD) as well as practitioners’ beliefs about medications for OUD. Over half (55 percent) ranked stigma as the highest barrier among other factors such as time and staffing, medication diversion, and organizational/clinic barriers.